Among the many impediments to the development of successful strategies to treat brain tumors are problems of drug delivery and an incomplete understanding of the tumor microenvironment, in particular, the innate and adaptive immune response within the brain. Using the brain ventricle as a window to this microenvironment, we explored for the first time the pharmacodynamics of complement activation within the CSF upon intrathecal rituximab administration.
Statement of Translational Relevance
Among the many impediments to the development of successful strategies to treat brain tumors are problems of drug delivery and an incomplete understanding of the tumor microenvironment, in particular, the innate and adaptive immune response within the brain. Using the brain ventricle as a window to this microenvironment, we explored for the first time the pharmacodynamics of complement activation within the CSF upon intrathecal rituximab administration.
In addition, we applied data generated from two recent phase I trials of intraventricular rituximab in recurrent central nervous system lymphoma to develop and validate a novel, compartmental pharmacokinetic model that describes monoclonal antibody distribution after intraventricular administration in humans. We demonstrated rapid complement activation in CSF that may contribute to the lymphocytoxic effects of intraventricular rituximab. Distribution of rituximab was measured via CSF and blood samples and supported a three-compartment pharmacokinetic model with rituximab penetration into the brain. We hypothesize that this information may provide insights into the basis for efficacy of intraventricular rituximab in the treatment of lymphoma within the neuroaxis, and be of general relevance to the development of novel therapeutic strategies for brain diseases that are based upon the intra-CSF administration of therapeutic antibodies and other macromolecules.
INTRODUCTION
Since the first serotherapy trial using a monoclonal antibody was performed in 1980, immunotherapeutic approaches based upon recombinant antibody technology have come to transform clinical practice in a variety of disciplines.
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In particular, the introduction of the anti-CD20 antibody rituximab has dramatically impacted the management of patients with B-cell malignancies and other disorders related to B-cell pathology. 2 The now widespread utilization of recombinant antibodies to treat human disease has prompted significant interest in analyses of their safety, mechanisms of action and resistance, pharmacokinetics and distribution, and combinatorial use with other agents. 3, 4 While agents such as trastuzumab and rituximab improve outcomes in systemic HER2-positive breast cancer and B-cell non-Hodgkin's lymphoma respectively, there is evidence that the blood-brain-barrier significantly attenuates efficacy of immunotherapeutic approaches for brain tumors that involve systemic administration of protein macromolecules. [5] [6] [7] [8] [9] For this reason, several investigators have evaluated intrathecal administration of antibodies such as rituximab or trastuzumab, to bypass the blood-brain-barrier and induce responses of CNS lymphoma or breast cancer brain metastases. 10 11-13 14-27 Our group recently performed the first dose escalation studies of the intrathecal administration of a naked monoclonal antibody (rituximab). An initial study was performed in cynomologus monkeys, followed by two multicenter Phase I trials in patients with recurrent CNS lymphoma. 10, 13, 22 In the first clinical study, we evaluated rituximab as monotherapy, administered primarily via the intraventricular route. In the second, we
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Intraventricular rituximab was well-tolerated at the 10 and 25 mg dose levels, as monotherapy and in combination with methotrexate, and induced responses not only within the cerebrospinal fluid (CSF) but surprisingly, also within the intraocular compartment and in non-bulky lesions (< 2 cm) within brain parenchyma. Activity was detected in patients with disease recurrent or refractory to intravenous rituximab, independent of steroid administration.
Similar results using intrathecal rituximab and trastuzumab have been described by other investigators in case reports and small clinical series. 10 11-13 14-27 These positive results have been somewhat surprising given the concept of the central nervous system (CNS) as an immunologically privileged site, assumed to be devoid of significant concentrations of complement mediators 28 and immune effector cells and because of the presumption that macromolecules administered within the CSF are unable to penetrate brain parenchyma.
Because the CSF is specialized to bathe the brain and spinal cord and is not exposed to the systemic circulation, there is significant representation of CNS-relevant inflammatory cells and protein constituents within its approximate 150 ml volume.
We previously described the first large-scale proteomic analysis of CSF to identify CSF proteins that reproducibly distinguish CNS lymphoma from benign conditions. 29 While a significant proportion of these peptides are associated with lymphoma invasion and extracellular matrix, most of the upregulated CSF peptides identified involve the innate immune response,
Research. including CD14, a marker of monocyte activation, as well as activating and inhibitory components of the complement cascade. 29 In addition, Pulido and colleagues recently demonstrated selective penetration of rituximab (molecular weight 145 kD), into full-thickness retina, in contrast to tissue plasminogen activator (70 kD), after intravitreal injection. 30 Similar results were obtained with bevacizumab. 31 Moreover, the intraventricular administration of neurotrophic proteins has reproducibly been demonstrated to induce neurogenesis in deep brain structures, including thalamus and substantia nigra in mouse models. [32] [33] [34] Taken together, these findings implicate existence of selective mechanism(s) that facilitate transport of macromolecules from CSF or vitreous into neural tissues.
We previously described a pharmacokinetic (PK) model of rituximab disposition after intraventricular injection in cynomologus monkeys which predicts a three-compartment model with distinct rate constants for rituximab distribution from CSF to serum and from CSF to brain tissue. The goals of this study are to: (1) define the pharmacodynamics of complement activation within the CSF upon intrathecal rituximab administration, and (2) utilize PK data from two recent phase I trials in CNS lymphoma to describe the disposition of rituximab after intraventricular administration in humans. We hypothesize that this information will yield insights into the basis for efficacy of intraventricular rituximab in the treatment of lymphoma within the neuroaxis, as well as be relevant to the development of novel therapeutic strategies for brain diseases that are based upon the intra-CSF administration of therapeutic macromolecules.
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METHODS

Study Population
CSF and blood specimens from subjects were obtained after informed consent in accordance with Institutional Review Board-approved protocols at the University of California, San Francisco. Ten subjects were treated in the first phase I trial of intraventricular rituximab (median age 55.5, range 28-82; seven males, three females). Fourteen subjects were treated in the second phase I trial of intraventricular rituximab plus methotrexate (median age 61, range 37-75; seven males, seven females). Traumatic CSF specimens were excluded.
Immunohistochemistry
Frozen sections were immunostained with monoclonal anti-complement C3 (Quidel). Anti-Iba-1 antibody was from Abcam. Immunoreactivity was visualized as described. 35 Confocal imaging was performed using a Zeiss LSM510 NLO Meta microscope with multi photon (800nm), 488nm and 543-nm laser excitation.
In situ hybridization
Full-length human complement C3 cDNA in pBluescriptSK(-) was from American Type Culture Collection and verified by resequencing. In situ hybridization was performed using digoxigenin-labeled riboprobes, as described. Samples were processed using a NuGEN FL-Ovation™ cDNA Biotin Module V2.
Quantitative RT-PCR analyses were performed using human complement C3 probe and normalized to GAPDH (ABI). 
Bioanalysis
CSF and serum concentrations of rituximab were determined using a validated ELISA. 36 The lower limit of quantification for rituximab was 0.250 μg/mL for CSF and 0.500 μg/mL for serum.
Pharmacokinetic Data Analysis
Rituximab CSF and serum concentration data were modeled simultaneously using nonlinear mixed effects modeling (NONMEM VII version 7.2.0, ICON).
Graphical evaluation of NONMEM outputs was performed using S-PLUS 8.0 for Windows (Insightful). The first-order conditional estimation with interaction (FOCEI) method was used for population PK analyses. PK parameters were derived using POSTHOC step in NONMEM. CSF and serum concentrations below the lower limit of quantitation were assigned as missing. 
Complement Activation in CSF
Given the rapid lymphocytotoxic effects of rituximab observed in the treatment of leptomeningeal lymphoma, we evaluated the possibility of activation of the complement cascade in CSF in CNS lymphoma patients treated with intraventricular rituximab. des-arg to evaluate the temporal relationship between rituximab administration and complement activation in CSF.
Intraventricular rituximab monotherapy was reproducibly associated with complement activation in each of the nine study subjects examined, at each of the three dose levels: 10, 25 and 50 mg rituximab.
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Mean baseline C3a desarg in CSF in these phase I trial subjects was 28.56 ng/ml (range 5.9-60 ng/ml).
Within one-to-two hours of intraventricular rituximab administration, C3a des-arg achieved peak concentrations within CSF (mean 74.6 ng/ml, range 12-181 ng/ml) followed by a decline to baseline or below within 24 hours ( Figure 2A ).
Notably, the rapid onset of complement activation was observed to temporally correlate with anti-lymphoma cytologic effects in responding patients with leptomeningeal disease.
Increased C3a generation was confirmed by immunoblot using an anti-C3a-specific monoclonal antibody ( Figure 2B ). In parallel, generation of the C5b-9 complex within the CSF was also detected which reproducibly demonstrated immunoreactivity of C3 protein that was localized to the cytoplasm of CNS lymphoma-associated macrophages and microglia, identified by Iba-1 expression.
39, 40
Spontaneous Complement Activation in CNS Lymphomas
To further define the relationship between complement activation and the pathogenesis of CNS lymphoma, we compared baseline C3a des-arg concentrations in CSF obtained from 27 HIV-negative patients with non- The determinants of rituximab response and/or resistance in CNS lymphoma may also relate to its
pharmacokinetics and distribution upon intraventricular administration, parameters which have not previously been presented.
Intraventricular Rituximab Pharmacokinetics
Eighty-five (85) rituximab serum samples and 135 CSF samples were collected from 10 patients in the first trial for PK analyses. Where t is the sample time, A1, A2, and A3 are the amount of drug in the CSF, serum and brain tissue respectively. K12, K13, and K31 represent the distribution rate constants from CSF to serum (12) , from CSF to brain tissue (13), and from brain tissue to CSF (31), respectively. Potential efflux of the drug from the serum compartment to CSF was ignored in this model, justified based on the experimental observation that the concentration of monoclonal antibody in the CSF after intravenous dosing is greater than 1,000 times lower than the serum concentration. 42 Therefore, the potential contribution to the CSF concentration from serum compartment efflux to CSF is expected to be insignificant. A representative individual fit of the model to both CSF and serum concentration is depicted in Figure 4 as well as the goodness-of-fit plots for the full data set and the population-based compartmental PK model used ( Figure   4C and D). Overall, the three-compartmental PK model with the brain tissue compartment effectively describes both serum and CSF PK data.
Research. clearance between CSF and serum (Q) and between CSF and brain tissue (CLd) were 208 and 189 mL/day respectively, and the calculated volume of distribution in brain tissue (V3) was 320 mL. The elimination clearance from the serum compartment, CL was 332 mL/day, associated with median terminal elimination half-life from serum was 21.1 days, which was consistent with rituximab elimination half-life previously described after intravenous administration. 43 
Pharmacokinetic Evidence for Rituximab Penetration in Brain
The observed biphasic disposition profiles in CSF provide supportive evidence for rituximab penetration in brain tissue. In order to better understand if the biphasic curve is a consequence of rituximab penetration within brain tissue after intraventricular administration, the final compartmental pharmacokinetic model was used to perform a theoretical sensitivity analysis on the V3 parameter. When V3 is equal to 0 mL, meaning to assume that there is no brain tissue compartment, a much faster decline (i.e., mono exponential decline) of rituximab concentration is observed in CSF, indicating that there does not exist a second biological compartment besides the CSF for drug disposition. As the V3 increases, a second elimination phase (bi-phasic) in the CSF appears (Supplemental Figure 2) . The biphasic disposition profiles in CSF observed using this model also provide supportive evidence for rituximab penetration in brain tissue.
Validation of the PK Model in a Second Phase I Study
The utility of this three-compartment pharmacokinetic model is specimens from a CNS lymphoma patient could barely be detected. 44 Our results therefore identify one mechanism by which intraventricular rituximab may overcome the blood-brain barrier to mediate cytotoxicity against otherwise drugresistant recurrent NHL. Nevertheless, while the time course of complement activation correlates with the onset of B-cell lysis in CSF, other mechanisms of rituximab-mediated efficacy such as antibody-dependent cellular cytotoxicity also likely contribute in this setting.
In addition, we demonstrate upregulation of C3 protein not only within the CSF but also within brain parenchyma. Given the pharmacokinetic evidence for brain penetration of rituximab, these results raise the possibility that rituximabinduced activation of the complement cascade within the brain may have the capacity to elicit anti-tumor responses throughout the neuroaxis, a result which has implications for the intravenous route of administration as well. In support of this hypothesis is our demonstration of the expression of the C5b-9 membrane attack complex not only within the CSF but also diffusely within 3 consecutive CNS lymphomas specimens analyzed (unpublished results). We also detected spontaneous complement activation within the CSF of patients with other types of brain tumors, including metastatic carcinoma and glioma (not shown).
Somewhat surprisingly, high levels of the C3 cleavage product C3a were found to be associated with inferior prognosis in independent populations of CNS lymphoma patients.
The activating signal for spontaneous complement activation within brain tumors is undefined. One possibility is that C3 convertase activity is mediated via the lectin pathway which may occur by presentation of An emerging body of data implicates complement activation in the pathogenesis of multiple sclerosis and other neuro-inflammatory and/or neurodegenerative diseases. 45 46, 47 48, 49 The fact that we demonstrated significantly higher levels of complement activation in CNS lymphoma compared to these and other nonmalignant neurologic conditions underscores the potential physiologic significance of C3 activation in CNS lymphoma and other brain tumors.
An important question which emerges from these studies is the mechanism by which constitutive activation of complement C3 cleavage might promote CNS lymphoma progression. In addition to the generation of C3b which attenuates natural killer function, 41 activation of the complement cascade at the level of C5a may potentiate intratumoral chemotaxis of myeloid suppressor cells, which may disrupt adaptive anti-lymphoma immunity. 50 In addition, in experimental autoimmune encephalomyelitis, there is direct evidence that C3a itself promotes chronic inflammation in the CNS, as a chemoattractant. 51 There is also evidence that complement C3 and C3a promote growth signals in cancer and potentiate CXCL12 signaling. 
angiogenic effects of C3a and C5a on retinal vasculature. 
pharmacokinetics of intraventricular rituximab in a second, independent multicenter phase I trial. 22 The emerging body of data regarding the physiology of the complement system within the CSF in CNS lymphoma suggests several possible interventions to improve efficacy or to overcome resistance to intraventricular rituximab -for example, via the co-administration of pharmacologic inhibitors of complement antagonists such as clusterin, which is upregulated within the CSF in CNS lymphoma, as a means to potentiate rituximab-mediated cytotoxicty. Figure 2A .
Intraventricular rituximab administration (10 mg) was reproducibly associated with a time-dependent increase and decline in C3a concentration within the CSF, as demonstrated by ELISA determination of C3a des-arg. Figure 2B . Immunoblot analysis of C3a concentration in CSF using a monoclonal antiC3a antibody confirmed C3 cleavage in CSF after rituximab administration. Figure 2C . Intraventricular rituximab (10 mg) was also reproducibly associated with a time-dependent increase and decline in the concentration of the C5b-9, "membrane attack complex" within the CSF. Figure 2C depicts C5b-9 levels in the same patient as in Figure 2A and with a time course similar to the generation of C3a. Figure 2D . Serum concentrations of C3a after intraventricular rituximab (same patient as in FIgure 2A ). The C3a index (ratio of CSF:serum C3a divided by CSF:serum albumin) was 9 at baseline and increased to 50 at one hour post-rituximab, consistent with intrathecal C3 biosynthesis rather than passage through a disrupted blood-brain barrier. Determination of the C3a index in CSF in three consecutive subjects (treated at 10 mg, 25 mg and 50 rituximab dose levels), each supported the intratumoral production of C3a in tumor and CSF. Figure 3B . Anti-C3 immunohistochemical analysis of normal human brain tissue reveals weak immunoreactivity (x 10). Figure 3C . In situ hybridization with a C3 anti-sense probe demonstrates C3 mRNA synthesis in PCNSL, with strong expression by cells adjacent to tumor-associated vasculature (x 400). Figure 3D . In situ hybridization: negative control of PCNSL specimen using sense probe (x 10). Figure 3E . B-cell and CSF monocyte populations sorted with anti-CD11b and anti-CD14 antibodies. Patients. C3a des-arg concentration was markedly elevated in the CSF of patients with CNS lymphoma, including newly-diagnosed PCNSL (N=31, (30 DLBCL, 1 T-Cell NHL, median age 62) and relapsed CNS lymphoma (N=26, all DLBCL, median age 48) compared to patients with non-malignant, neuro-inflammatory, or neurodegenerative conditions (N=27, median age 54). (p=0.05) The cohort of patients with non-malignant neurologic conditions included cases of multiple sclerosis (N=6), encephalitides (N=5), transverse myelitis (N=3), two cases each of coccidiomycosis, dementia, normal pressure hydrocephalus, amyotrophic lateral sclerosis, epilepsy and one case each of neurosarcoid, cryptococcal meningitis, and Parkinsonism. Spontaneous C3 activation was also detected in the CSF of patients with brain metastases (N=13, median age 48), including breast cancer (N=6), non-small cell lung cancer (N=2), metastatic carcinoma, unknown primary (N=2), and one case each of metastatic sarcoma, germ cell tumor and small cell carcinoma of the lung. Figure 3L . Elevated C3a des-arg concentration in CSF is associated with short survival among 17 patients with recurrent CNS lymphoma treated with intraventricular rituximab therapy (10 mg and 25 mg) for recurrent CNS lymphoma. (All ventricular CSF). ECOG >1 was also associated with adverse prognosis in this cohort (P<0.0002). Notably, given that phase I trials are not designed to test efficacy, the significance of C3a as a prognostic variable is limited in this setting. Similar results were obtained in an independent cohort of 35 newly-diagnosed patients with CNS involvement of diffuse Figure 4B . Rituximab compartmental PK model after intraventricular injection in patients with CNS lymphoma. R0 = drug intraventricular injection; k13 = rate constant from CSF to brain tissue compartment; k31 = rate constant from brain tissue compartment to CSF; k12 = distribution rate constant from CSF to serum; k10 = elimination rate constant; CL = elimination clearance; Q = distribution clearance from CSF to serum; CLd=distribution clearance from CSF to brain tissue; V1 = CSF volume; V2 = serum volume; V3 = brain tissue volume. 
